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a b s t r a c t
We reviewed the natural history of patients with hypertrophic cardiomyopathy (HCM). The effect of
medical treatments on natural history, left ventricular (LV) functions and LV remodeling was also evalu-
ated. Sudden cardiac death and end-stage heart failure are the most serious complications of HCM. Age
<30 years and a family history of sudden premature death are risk factors for sudden cardiac death in
HCM patients. End-stage heart failure is not a speciﬁc additional phenomenon observed in patients with
HCM, but is the natural course of the disease in most of those patients. After the occurrence of heart
failure, the progression to cardiac death is very rapid. Young age at diagnosis, a family history of HCM,
and greater wall thickness are associated with a greater likelihood of developing end-stage heart failure.
Neither beta-blockers nor calcium antagonists can prevent this transition.
The class Ia antiarrhythmic drugs, disopyramide and cibenzoline are useful for the reduction of LV
pressure gradient. Unlikedisopyramide, cibenzolinehas little anticholinergic activity; therefore, this drug
can be easily adapted to long-term use. In addition to the reduction in LV pressure gradient, cibenzoline
can improve LV diastolic dysfunction, and induce regression of LV hypertrophy in patients with HCM. A
decrease in intracellular Ca2+ concentration through the activation of the Na+/Ca2+ exchanger associated
with cibenzoline therapy is likely to be closely related with the improvement in HCM-related disorders.
It is possible that cibenzoline can prevent the progression from typical HCM to end-stage heart failure.© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The ﬁrst report of hypertrophic cardiomyopathy (HCM) was by
eare in 1958 [1]. More than 50 years have passed since his ﬁrst
eport, but our understanding of the natural history of HCM and
he optimum therapy for this disease are still insufﬁcient.
Sudden cardiac death and end-stage heart failure are the most
erious complications in HCM. A recent study indicated that HCM
as the leading cause of sudden cardiac death among runners [2].
lthough these serious complications are known to occur more
ften in patients with hypertrophic obstructive cardiomyopathy
HOCM) than in patients with hypertrophic nonobstructive car-
iomyopathy (HNCM) [3], they are not rare in HNCM patients.
ontrol of these serious complications has been difﬁcult, so in 2009
CM was designated as the ﬁftieth intractable disease in Japan.
Two essential cardiac disorders have been identiﬁed in patients
ith HCM: left ventricular (LV) hypertrophy and LV diastolic dys-
unction. We believe that the effects of beta-blockers and calcium
ntagonists are too weak to control these essential cardiac disor-
ers. Thus, these drugs cannot improve the long-term prognosis
n patients with HCM. In 1982, Pollick published the ﬁrst report
hat the class Ia antiarrhythmic drug, disopyramide was useful for
he attenuation of LV pressure gradient (PG) [4]. In 1988, Sherrid
t al. conﬁrmed the usefulness of disopyramide for the reduction
f LVPG [5]. We have reported that another class Ia antiarrhyth-
ic drug, cibenzoline was useful for the reduction of LVPG [6,7].
nlike disopyramide, cibenzoline has little anticholinergic activity
8]; therefore, this drug can be easily adapted to long-term use.
n addition, it has been conﬁrmed that cibenzoline improves LV
iastolic dysfunction, not only in patients with HOCM, but also in
atients with HNCM [9].
In this paper, we provide an overview of the natural history
f HCM, and we examine the effect of beta-blockers and calcium
ntagonists on the natural history and LV remodeling in patients
ith thisdisease. In addition, theeffects of disopyramideandciben-
oline on LVPG, LV functions and LV hypertrophy in patients with
CM are discussed.
atural history of HCM
HCM is a primary cardiac disease that is usually genetically
ransmitted as an autosomal dominant trait [10]. The natural his-
ory of HCM is variable and includes patients who remain clinically
table and relatively symptom-free for long periods of time, as well
s those who experience premature death that is sudden or due
o progressive end-stage heart failure. Hecht et al. examined the
ccurrence of two distinctive phases of the natural history of HCM,
udden cardiac death and end-stage heart failure in seven selected
amilies known to have genetically transmitted HCM [11]. In that
tudy, the 7 families comprised 128 relatives; 26 died suddenly and
developedend-stageheart failure. Patientswhodied suddenlydid
o at younger ages than did those who died in the end-stage phase
fHCM (23±10 years vs. 42±8 years, p<0.001). These results indi-
ate that theremay be variations in the natural history proﬁle, such
s sudden cardiac death and end-stage heart failure, even among
losely related patients who share an identical genetic substrate.
hese two divergent expressions of HCM occur during different
eriods of life.
udden cardiac deathSudden cardiac death is deﬁned as instantaneous collapse with
ubsequent death occurring within minutes [12]. In patients with
CM, “sudden” usually means a very short time, and usually
atients die with little sufferings. Thus, many patients with HCMrdiology 64 (2014) 1–10
who die suddenly are often found after death. These characteris-
tics contribute to the difﬁculty of elucidating the mechanisms of
sudden cardiac death in HCM.
The clinical proﬁle of 78 patients with HCM who died sud-
denly was analyzed by Maron et al. [12]. At the time of the cardiac
event, 71% of the patients were younger than 30 years of age,
54% were without functional limitation and 61% were performing
minimal physical activity. In addition, in this study, the patients
with HCM who died suddenly could not be identiﬁed by clinical,
hemodynamic, or morphologic measurements, i.e., LVPG at rest,
LV end-diastolic pressure, electrocardiographic pattern, or degree
of ventricular septal thickening. The investigators also reported no
signiﬁcant difference in the incidence of syncope between theHCM
patients who suffered sudden death and the surviving controls.
This ﬁnding conﬂicts with that of McKenna et al., who reported
that syncope was more common among patients with HCM who
died suddenly [13]. Maron et al. identiﬁed two clinical variables as
reliable markers for identifying the subgroup of patients with HCM
whowere at increased risk for suddendeath. First, a familial history
of sudden premature death may constitute a risk factor in certain
families with unusually virulent expressions of HCM [14]. Second,
24-h ambulatory electrocardiographicmonitoringmay be useful in
identifying certain patients with HCM who are at increased risk for
sudden death [15]. Fig. 1 shows a family pedigree with many sud-
den premature deaths. Subjects who had suffered or are suffering
from HCM are shown in red. The proband in this HCM family is a
39-year-old male patient, and nos. 1, 2, and 3 are treated in our
clinic.
End-stage heart failure
Some patients with HCM evolve into a phase characterized by
systolic dysfunction, LV dilation, and wall thinning, resembling
the morphologic and functional features of dilated cardiomyopa-
thy (DCM). Much of the prior literature about this end-stage phase
of HCM is conﬁned to isolated cases or small groups of patients
[16–21]. We have reported that it takes about 15 years to progress
from typical HCM to the end-stage phase of heart failure, and
that this is not a phenomenon observed in a special class of
patients with HCM, but is the natural course observed in most
HCM patients [22,23]. Young age at diagnosis, a family history of
HCM, and greater wall thickness are associated with a greater like-
lihood of developing end-stage heart failure [24,25]. In addition,
Harris et al. indicated that only 23 patients (55%) with end-stage
heart failure showed the most complete remodeling, where many
patients with end-stage heart failure did not exceed the outer lim-
its for LV cavity size [25]. The prognosis in patients with HCM
who have end-stage heart failure is very poor, so the options of
cardioverter-deﬁbrillators implantations [25] or heart transplan-
tation [24] deserve consideration on the ﬁrst appearance of heart
failure.
The mechanisms responsible for the progression from typical
HCM to the end-stage phase are unresolved, but a molecular or
genetic abnormality may be involved [26–28]. However, the exact
description about the relationship between the genetic abnormal-
ity and myocardial injury or myocardial necrosis was not given.
Nagata et al. for the ﬁrst time reported that cardiac enzyme abnor-
malities may be related to abnormal thallium perfusion in patients
with familial HCM [29]. We also reported a patient with HCM
whose persistent elevation of plasma cardiac enzymes of CK-MB
and LDH1 was closely related to the evolution to DCM-like fea-
tures [21]. In addition, we also reported the elevation of CK-MB
activity and MMa activity of CK-MM isoform, which is known
to be sensitive marker of myocardial injury due to myocardial
infarction [30], was observed in patients with HCM who have
typical LV morphologic pattern [31]. Recent reports indicated
M. Hamada et al. / Journal of Cardiology 64 (2014) 1–10 3
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iFig. 1. A family pedigree of “Malignant” hypertrophic cardiomyopath
hat high-sensitivity cardiac troponin T was elevated in patients
ith HCM [32,33]. We think that the elevation of these cardiac
nzymes is closely related to the evolution from typical HCM to
nd-stage heart failure, and the persistent elevation of cardiac
nzymes is mainly due to myocardial ischemia. Recent review
y Kawasaki and Sugihara suggested the importance of myocar-
ial ischemia in the change of LV hemodynamics in patients with
CM [34]. We reported that myocardial ischemia was one of the
mportant factors which induced the elevation of plasama atrial
nd brain natriuretic peptides [35,36]. The elevation of plasma
trial and brain natriuretic peptides was reported in patients
ith HCM whose LV function was higher than that in normal
ontrol subjects [37]. Thus, the elevation of both natriuretic pep-
ides in patients with HCM may be a reﬂection of myocardial
schemia.
Fig. 2 shows a patient who evolved from typical HCM to end-
tage heart failure. Fig. 2 shows the electrocardiographic changes
A) and echocardiographic changes (B) in 58-year-old patient with
CM [22]. The electrocardiograms in a, b, and c were recorded
n 1982, 1986 and 1989, respectively. As shown in the ﬁgure,
V1+RV5, which is known to be a reﬂection of LV hypertrophy
38], gradually decreased as time passed. In addition, as shown in
eads V5 and V6, a notched R wave on the ECG, a predictor of a
egional scar pattern [39], usually appears as the ﬁrst ﬁnding of
yocardial injury. This ﬁnding progresses to more leads as the
yocardial injury advances, along with the decrease in SV1+RV5.
chocardiograms a and b in Fig. 2 were recorded in 1982 and 1989.
s shown in the ﬁgure a marked decrease in interventricular septal
all thickness andLVposteriorwall thickness, andan increase in LV
imensions were observed. This patient also exhibited persistent
levation of serum levels of cardiac enzymes LDH1 and CK-MB. The
atient died suddenly of arrhythmia. Fig. 2C shows the histopatho-
ogical ﬁndings on Azan–Mallory staining. Images a, b, c, and d are
rom the interventricular septum (400×), anterior wall (100×), lat-
ral wall (100×) and posterior wall (100×), respectively. Severe
yocardial ﬁbrosis was found in all regions, disarrayed cardiac
uscle was found in a, and wall thickening of a small artery was
ound in d.
The morphologic and functional features in many HCM patientsith end-stage heart failure resemble those in patients with DCM.
f a typical HCM pattern has not been identiﬁed, the HCM patient
ith end-stage heart failure may be mistakenly diagnosed as hav-
ng DCM..: sudden cardiac death; I.C.D: implantable cardioverter defbrillator.
We compared for the ﬁrst time the extent of LV remodeling on
the occurrence of LV heart failure in patients with HCM and DCM,
and we also compared the prognosis after the occurrence of heart
failure in the two groups [40,41]. There were 26 in the HCM group
(mean age: 54±18 years) and 72 in the DCM group (49±12 years).
In patients with HCM, the mean follow-up period from the initial
visit to our hospital to the onset of LV heart failure was 146±44
months. Fig. 3A and B shows the comparisons of LV remodeling.
Both LV end-diastolic and end-systolic dimensions were smaller
in the HCM group than in the DCM group. Fractional shortening
was greater in the HCM group than in the DCM group. Thus, the
severity of LV remodeling was less in the HCM group than in the
DCM group. However, the incidence of cardiac death was much
higher in the HCM group than in the DCM group, as shown in
Fig. 3C. Fig. 3D shows the cumulative survival rate for the HCM
and DCM groups and demonstrates that the HCM group showed
much poorer survival. This conﬂict between LV remodeling and
prognosis observed in the HCM group may be mainly due to under-
estimation of the true LV remodeling. We believe that the extent
of myocardial ﬁbrosis in HCM is so severe that the left ventricle
cannot dilate sufﬁciently; in other words, this is a defect of LV
preload reserve. Recently, two papers also reported the compar-
isons of LV remodeling and prognosis in end-stage heart failure
between HCM and DCM [42,43]. Results in both papers were the
same as ours. Consistent results in these papers are that patients
with HCM are the very poor prognosis after the occurrence of heart
failure.
Beta-blockers and calcium antagonists
In Japan, only beta-blockers and calcium antagonists
are permitted for use in the treatment of patients with
HCM.
Beta-blockers
In the 1960s, beta-blockers were mainly used for the reduction
of LVPG in patientswith hypertrophic subaortic stenosis [44]. How-
ever, the effect of beta-blockers in attenuating resting LVPG was
very weak [45,46]. However, there was a report that beta-blockers
were effective in improving clinical symptoms in both HOCM and
HNCM [47]. It is generally accepted that beta-blockers do not
improve LV diastolic function in patients with HCM. However,
there was a report that the A-wave ratio in the apex cardiogram
4 M. Hamada et al. / Journal of Cardiology 64 (2014) 1–10
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s reduced by treatment with propranolol [48]. This ﬁnding may
ndicate that the decrease in heart rate associated with propranolol
reatment results in an increase of blood ﬂow from the left atrium
o the left ventricle. An increase in stroke volume and a decrease
n left atrial load could improve the clinical symptoms in patients
ith HCM.
Syncope is one of the important symptoms in patients with
CM. We reported a male patient with HOCM who had a syncopal
ttack without arrhythmia during catheterization [49]. The hemo-
ynamic characteristics were low blood pressure due to low stroke
olume. Following intravenous propranolol administration, the
atient immediately regained consciousness and showed recovery
f blood pressure and stroke volume. Thus, we believe propranolol
s indispensable in relieving emergency symptoms in patients with
CM.
alcium antagonists
In the 1970s, calcium antagonists, mainly verapamil were
sed for the treatment of patients with HOCM. Kaltenbach et al.
eported that the long-term use of verapamil improved the clin-
cal symptoms and LV function in patients with HOCM [50]. It is
cknowledged that verapamil improves LV diastolic function in the
arly diastolic phase [51–53]. The intracellular Ca2+ concentration
f myocytes is known to be very high in patients with HCM, and
ppears to be related to abnormal LV diastolic dysfunction [54,55].
hus, it is reasonable touse calciumantagonists for the treatmentof
atientswithHCM.However, since calciumantagonists sometimesrocardiographic changes, (B) echocardiographic changes, and (C) histopathological
entricular posterior wall.
increaseLVPG[56], care isneededwhenusing theminpatientswith
HOCM.
Combination of beta-blockers and calcium antagonists
We retrospectively examined the effectiveness of beta-blockers
and calcium antagonists in patients with HCM. The changes in
LV remodeling and the prognosis were examined in 41 patients
with HOCM who were treated with a combination of beta-
blockers and calcium antagonists. The mean follow-up period
was 152±56 months. The results are summarized in Fig. 4. As
shown in Fig. 4A and B, with regard to myocardial hypertrophy,
SV1+RV5 decreased signiﬁcantly, and both interventricular sep-
tal wall thickness and LV posterior wall thickness also decreased.
As shown in Fig. 4C, LV end-diastolic dimension and left atrial
dimension both increased signiﬁcantly, whereas, fractional short-
ening decreased. These results indicate that combination therapy
with beta-blockers and calcium antagonists could not control the
progressive LV remodeling from typical HCM to end-stage heart
failure. Fig. 4D shows the complications during the follow-up
period. Heart failure and atrial ﬁbrillation appeared in more than
60% of the patients with HOCM during the follow-up period; in
addition, 61% of the patients died of heart failure or sudden cardiac
death.In conclusion, beta-blockers are effective in relieving clini-
cal symptoms, especially in patients with HOCM, and calcium
antagonists are effective in attenuating LV diastolic dysfunction,
especially in patients with HNCM. However, we believe that both
M. Hamada et al. / Journal of Cardiology 64 (2014) 1–10 5
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eta-blockers and calcium antagonists are of little use for preven-
ing the change from typical HCM to end-stage heart failure.
lass Ia antiarrhythmic drugs, disopyramide and cibenzoline
In 1982, Pollick [4] reported an epoch-making discovery con-
erning the treatment of patients with HCM: disopyramide was
he ﬁrst class Ia antiarrhythmic drug that could deﬁnitely attenuate
VPG in patients with HOCM. We have also reported that another
lass Ia antiarrhythmic drug, cibenzoline, is useful for the reduction
f LVPG [6,7]. In this section, we explain and evaluate the contri-
ution of class Ia antiarrhythmic drugs to the treatment of patients
ith HCM.
isopyramide
Pollick and Sherrid et al. conﬁrmed the usefulness of disopy-
amide for the reduction of LVPG [4,5]. Its mechanism of action in
educing LVPG appears to be due to a decrease in negative inotropic
ction [57,58]. Pollick et al. also considered that the decrease in
V end-diastolic pressure observed in their studies was due to a
ombination of the reduction in LVPG and the decrease in mitral
egurgitation [59]. There have been few reports about the effect of
isopyramide on LV diastolic function. We reported that disopyra-
ide, similar to diltiazem, could improve LV diastolic dysfunction
n patients with HNCM [53].
Sherrid et al. reported the long-term efﬁcacy and safety ofisopyramide in patients with HOCM [60]. They compared clin-
cal and echocardiographic data from 118 patients with HOCM
reated with disopyramide at 4 HCM treatment centers with the
ata in 373 patients not treated with disopyramide. The mean ageis in patients with HCM and patients with dilated cardiomyopathy (DCM) [40].
of the 118 HOCM patients was 47±20 years (range 1 month to 94
years), and the mean follow-up period was 3.1±2.6 years (range
0.2–18 years). The highest dose of disopyramide administered was
432±181mg/day (range 150–900mg/day). Disopyramide con-
trolled the clinical symptoms and LVPG in 78 patients (66%),
while the other 40 patients (34%) could not be satisfactorily
managed with disopyramide and thus, required major inva-
sive interventions. In the former group, the mean NYHA class
improved from 2.3±0.7 to 1.7±0.6, and LVPG decreased sig-
niﬁcantly from 75±33mmHg to 40±32mmHg. In the latter
group, NYHA class remained unchanged, and LVPG changed non-
signiﬁcantly from 73±35mmHg to 63±31mmHg. Fig. 5 shows
a Kaplan–Meier survival plot for all-cause cardiac mortality in
the disopyramide-treated and non-disopyramide-treated patients
with HOCM. There was no signiﬁcant difference. Nor was there
any signiﬁcant difference between the groups in terms of sud-
den cardiac death. In this study, only about 5% of the patients
were unable to tolerate the anticholinergic activity of disopyra-
mide, and proarrhythmia was not observed. In addition, marked
QT-interval prolongation was not identiﬁed. Based on these ﬁnd-
ings, the authors recommended the use of disopyramide in
patients with HOCM before proceeding to invasive interven-
tions.
The results of this study are generally acknowledged. However,
although it described changes in NYHA class and LVPG, it did not
demonstrate any inﬂuence of disopyramide on LV functions or LV
hypertrophy. In addition, therewasnodiscussionof the reasonwhy
a third of the patients did not respond to disopyramide treatment.
In addition, the investigators did not describe themechanismof the
reduction of LVPG associated with disopyramide treatment.
6 M. Hamada et al. / Journal of Cardiology 64 (2014) 1–10
  
A C
DB
F ertrop
c
C
8
d
b
s
a
W
b
t
T
d
O
o
H
L
l
h
c
c
t
i
i
e
o
300mgper day. Cibenzoline acts to decrease the plasma sugar level
[63]. In patients whose fasting plasma sugar levels are <70mg/dL,
cibenzoline is administered in a dose of 200mg per day.
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ibenzoline
In 1995, we administered cibenzoline for the ﬁrst time to an
2-year-old female patient with HOCM who was suffering severe
yspnea due to a high LVPG more than 200mmHg. Her LVPG had
een controlled by treatment with disopyramide. Because of the
trong anticholinergic activity, she stopped taking disopyramide,
nd 3 days after discontinuing the drug she complained of dyspnea.
ith her son’s permission, we initially tried 100mg of cibenzoline,
ut the LVPG was not attenuated; however, after the administra-
ion of another 100mg of cibenzoline, LVPG almost disappeared.
he most interesting surprise was a marked improvement in LV
iastolic dysfunction together with the disappearance of the LVPG.
ur study was approved by the Human Investigations Committee
f Ehime University Hospital (No. 14-24 in 2002) and Uwajima City
ospital (No. 24 in 2003).
VPG
Wehave reported that the class Ia antiarrhythmicdrug, cibenzo-
inewaseffective for reducingLVPGboth inpatientswith idiopathic
ypertrophic subaortic stenosis [6] and in patients with HOCM
aused by mid-ventricular obstruction [7]. Chronic treatment with
ibenzolinewas performed after the acute effect of oral administra-
ion of 200mg cibenzoline had been conﬁrmed. An improvement
n LVPG and LV functions was observed 2h after the oral admin-
stration, the time at which the maximal plasma concentration is
xpected [61]. Fig. 6 shows the acute effect of 200mgof cibenzoline
n LVPG inpatientswith idiopathic hypertrophic subaortic stenosishy, LV end-diastolic dimension, left atrial dimension, LV fractional shortening and
(A) and in patients with HOCM caused by mid-ventricular obstruc-
tion (B) [40,41]. As shown in the ﬁgure, LVPG was attenuated in
all patients of both groups. Kondou et al. reported that cibenzo-
line was useful to decrease the elevation of LVPG during dynamic
exercise [62]. The dose of cibenzoline used for chronic treatment isNon-Disopyramide 
Disopyramide 
373 319 300 269 237 203 167 141 
118 109 92 75 48 36 26 16 
Fig. 5. Kaplan–Meier survival curve for all cause cardiac mortality in disopyramide-
treated and non-disopyramide-treated patients with HOCM [59].
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V systolic and diastolic functions
The short-term effects of cibenzoline on LV systolic function
ere characterizedbyadecrease in fractional shortening andapro-
ongation of the pre-ejection period [6]. Both fractional shortening
nd pre-ejection period are sensitive markers of myocardial con-
ractility. Thus, these results indicate that cibenzoline has a potent
egative inotropic action. Systolic function estimated by fractional
hortening is usually greater in patients with HCM than in normal
ontrol subjects [64]. In our experience, systolic function inpatients
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with HCM treated with cibenzoline is close to that in normal con-
trol subjects at the chronic stage, but never decreases to a lower
level than in controls.
Fig. 7 shows the acute effect of 200mg cibenzoline on LV dia-
stolic functions (A: peak lengthening speed of LV posterior wall,
B: E/A ratio, and C: time to peak ﬁlling rate) in both patients with
HOCM and HNCM [9], and the effect of the intravenous adminis-
tration of cibenzoline on LV minimal pressure and LV end-diastolic
pressure in patients with HOCM and HNCM (D) [65]. As shown in
Fig. 7A–C, every LV diastolic function improved after the cibenzo-
line administration in all patients with both HOCM and HNCM. As
shown in Fig. 7D, LV minimal pressure and LV end-diastolic pres-
sure decreased in all patients with both HOCM and HNCM. Fig. 8A
and C shows LV pressures before the intravenous administration of
cibenzoline, and Fig. 8B and D shows LV pressures immediately
after the intravenous administration of cibenzoline in a patient
with HNCM [65]. As shown in Fig. 8A and B, peak systolic LV pres-
sure remainedunchanged,whereas LVdiastolic pressuredecreased
after the intravenous administration of cibenzoline. These results
indicate that the improvement of LV diastolic dysfunctions in
all patients with both HOCM and HNCM was not merely due to
the reduction in LVPG, but to the direct action of cibenzoline.
In addition, after the intravenous administration of cibenzolinesure and LV minimal pressure decreased, and the difference in
both pressures, which is closely correlated with E-wave velocity,
increased [65].
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V hypertrophy
LVPG and LV diastolic dysfunction in patients with HOCM can
e attenuated by treatment with cibenzoline. In order to amelio-
ate the myocardial ischemia, it is important to induce a regression
f LV hypertrophy. Fig. 9 shows the electrocardiographic changes
efore and after treatment with cibenzoline in a 48-year-old male
ith HNCM. Fig. 9A and B were recorded in 2004 and 2007, respec-
ively. The QRS voltage on the electrocardiogram in B was greatly
ecreased, and the negative T-wave had returned to positive. We
elieve that chronic treatment with cibenzoline may induce a
egression of LV hypertrophy in patients with HCM.
Fig. 9. Changes in electrocardiogram before (A) and 3 years after (B) the treavenous administration of cibenzoline in a patient with HNCM [65].
Mechanisms of the effect of cibenzoline
The intracellular Ca2+ concentration ([Ca2+]i) of myocytes is
known to be very high in patients with HCM; this appears to be
related to the LV diastolic dysfunction [54]. Palmiter and Solaro
[55] and Molkentin et al. [66] reported that the increase in [Ca2+]i
was closely associated with LV hypertrophy. Thus, it is postulated
that the LV diastolic dysfunction and LV hypertrophy in patients
with HCM are closely related to an increase in [Ca2+]i.A strong Na+ channel blocking action by cibenzoline results
in a decrease in the intracellular Na+ concentration ([Na+]i) of
myocytes, which in turn disturbs their depolarization. To prevent
atment with 300mg per day of cibenzoline in a patient with HNCM.
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Table 1
Effects of beta-blocker, calcium antagonist, disopyramide, and cibenzoline on LV pressure gradient, LV diastolic dysfunction, LV hypertrophy, and end-stage heart failure,
and side effects of each drug [32,33].
LV pressure
gradient
LV diastolic
dysfunction
Regression of LV
hypertrophy
End-stage
heart failure
Side effects
Beta-blocker ∼©    Contraindication to asthma and ASO
Calcium-antagonist ©∼ ©   Reverse effect to LV pressure gradient
Disopyramide ©∼ ©∼ ? ? Hypoglycemia
Anticholinergic activity
Cibenzoline ©∼ Hypoglycemia
 n.
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[
[
[
[
[
[
[
[
[
[: little or weak effect; : reverse effect; ©: effective; : very effective; ?: unknow
V: left ventricular; ASO: Arteriosclerosis Obliterans.
he decrease in [Na+]i, the Na+/Ca2+ exchanger (NCX) may be acti-
ated, and thus, the myocyte [Ca2+]i may decrease. This pathway
nderlies the decrease in myocardial contractility achieved with
he use of class Ia antiarrhythmic drugs. In fact, 2 h after the oral
dministration of 200mg of cibenzoline, LV fractional shortening
ecreased in patients with HCM [6]. Recent studies have shown
hat the NCX plays an important role in maintaining cellular Ca2+
omeostasis [67–69]. The NCX primarily extrudes Ca2+ from inside
o outside the cell during repolarization and diastole, which bal-
nces the entry of Ca2+ via L-type Ca2+ channels during cardiac
xcitation. A decrease in [Ca2+]i through the activation of NCX
ssociated with cibenzoline therapy is likely to be closely related
o the improvement of HCM-related disorders observed in this
tudy.
Two factors may be related to the decrease in LVPG. Usually,
ystolic function in HOCM is characterized by over-contraction
64], which is mainly due to a decrease in LV wall stress. There-
ore, one factor for the reduction of LVPG may be a suppression
f LV over-contraction by cibenzoline therapy, which results in
ecreasedmyocardial contractility. The data related to LV functions
nd LV remodeling in the chronic phase in patients with HOCM
ho are treated with cibenzoline indicate that the LV end-diastolic
imension is signiﬁcantly enlarged approaching the normal size,
hereas fractional shortening remains unchanged. Based on these
ata,webelieve that [Ca2+]i in patientswithHCMdoesnotdecrease
ess than [Ca2+]i in normal subjects, despite treatment with ciben-
oline. Thus, the other important mechanism for the reduction of
VPG may be this LV reverse remodeling.
onclusion
Table 1 shows our idea about the drugs which can be utilized
o patients with HCM in Japan. Taking the ﬁndings shown by a
ot of papers into the consideration, the original table [41] was
odiﬁed like this. The most important medical therapy to patients
ith HCM is to improve the LV diastolic dysfunction and induce
regression of LV hypertrophy in patients with HCM. When a
edical therapy cannot improve these two essential cardiac dis-
rders in patients with HCM, most patients progress from typical
CM to end-stage heart failure. Since the chronic therapy with
ibenzoline, we have had no patients with HCM whose fractional
hortening decreased less than normal subjects. Thus, we believe
he possibility that cibenzoline treatment can prevent the progres-
ion from typical HCM to end-stage heart failure. However, it is
ery difﬁcult to prevent the occurrence of sudden cardiac death
n patients with HCM. Even if the essential cardiac disorders in
atients with HCM can be controlled by the medical therapy, we
annot change LV architecture in HCM which is disorganized and
isarrayed cardiac muscle cells with bizarre shapes. Sudden car-
iac death in patients with HCM is the biggest problem to be
etermined.
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